^
BIOMARKER:

RAS wild-type

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
RAS wild-type
Colorectal Cancer
cetuximab
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
cetuximab + avelumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
regorafenib
Sensitive
:
A1
RAS wild-type
Colorectal Cancer
panitumumab
Sensitive
:
A1
RAS wild-type
Colorectal Cancer
fruquintinib
Sensitive
:
B
RAS wild-type
Colorectal Cancer
bevacizumab
Sensitive
:
B
RAS wild-type
Colorectal Cancer
ramucirumab
Sensitive
:
C2
RAS wild-type
Colorectal Cancer
bevacizumab + cetuximab
Sensitive
:
C2
RAS wild-type
Colorectal Cancer
EGFR inhibitor
Sensitive
:
C3
RAS wild-type
Colorectal Cancer
avelumab
Sensitive
:
C3
RAS wild-type
Colon Cancer
cetuximab
Resistant
:
C3
RAS wild-type
Colorectal Cancer
anlotinib
Sensitive
:
C3
RAS wild-type
Colorectal Cancer
cetuximab + tislelizumab
Sensitive
:
C3
RAS wild-type
Colorectal Cancer
EGFR inhibitor + VEGF inhibitor
Sensitive
:
C3
RAS wild-type
Colorectal Cancer
panitumumab + cabozantinib tablet
Sensitive
:
C3